Notes to Accounts of Emmessar Biotech & Nutrition Ltd.

Mar 31, 2024

b) The Company has not declared any Dividend.

c) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders

d) List of Shareholders holding more than 5% of the Total Number of Shares issued by the Company

34 : Commitments & Contingent Liabilities		(? in Lakhs]
Particulars	Year Ended	Year Ended
	31.03.2024	31.03.2023
a) Estimated Amount of Contract remains to be executed and not provided for in the accounts	NIL	NIL
b) Claims against the Company not acknowledges as Debts	NIL	NIL

The estimation of future salary increases considered in Acturial Valuation takes account of infaltion, seniority promotions, and other relevant factor on long term basis

D. Other Long Term Benefits

The Company does not have any other Long Term benefits

36 : Accounting Standard (Ind AS) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare,Fine Chemicals and Rent on Immovable property. Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts.All other expenses which are not attributable to segments have been disclosed as unallocable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

38 : Due to/ from parties are subject to confirmation

39 : In the opinion of the Board all the current Assets, Loans and Advances deposits are realisable at value stated in ordinary course of business

which are atleast equal to the amount at which they are stated in the books unless otherwise stated.

40 : As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign

currency to its non resident shareholders during the current year as well as previous year.

Deferred Tax Asset on unabsorbed depreciation and other temporary differences available as per the Income Tax Act, 1961 has been recognized, since it is probable that taxable profit will be available to adjust them in future years. Unabsorbed depreciation which forms a major portion of the Deferred Tax Asset can be carried forward and set off against profits for unlimited number of years under the Indian Income Tax Act, 1961; and profitability projections based on current refining margins show sufficient profits for set-off in future.

49 : OTHER DISCLOSURE UNDER SCHEDULE-III

1. No funds have been advanced or loaned or invested by the company to or in any other persons or entities, including foreign entities (Intermediaries) with the understanding, whether recorded in writing or otherwise, that the intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

2. No funds have been received by the company from any persons or entities, including foreign entities (Funding Parties) with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

3. The company does not have any contingent liabilities as on 31st March 2024

4. The Company does not have any long-term contracts including derivative contracts for which there are any material forseable losses.

5. No proceedings have been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988).

6. The Company has not been declared as wilful defaulter by any bank or financial Institution or other lender.

7. During the year, the company has not entered into any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956.

8. There are no transactions which have not been recorded in the books of accounts and which have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

9. A charge of INR 1,10,00,000/- created on 16.12.1994, remains unsatisfied despite the debt has been repaid.

10. The company does not have layers beyond the number prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017.

11. The company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

50 : Recent Pronouncements

Ministry of Corporate Affairs (“MCA”) notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. On March 31,2023, MCA amended the Companies (Indian Accounting Standards) Amendment Rules, 2023, as below:

Ind AS 1 - Presentation of Financial Statements - This amendment requires the entities to disclose their material accounting policies rather than their significant accounting policies. The effective date for adoption of this amendment is annual periods beginning on or after April 1, 2023. The Company has evaluated the amendment and the impact of the amendment is insignificant in the standalone financial statements.

Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors - This amendment has introduced a definition of ‘accounting estimates’ and included amendments to Ind AS 8 to help entities distinguish changes in accounting policies from changes in accounting estimates. The effective date for adoption of this amendment is annual periods beginning on or after April 1,2023. The Company has evaluated the amendment and there is no impact on its standalone financial statements.

Ind AS 12 - Income Taxes - This amendment has narrowed the scope of the initial recognition exemption so that it does not apply to transactions that give rise to equal and offsetting temporary differences. The effective date for adoption of this amendment is annual periods beginning on or after April 1,2023. The Company has evaluated the amendment and there is no impact on its standalone financial statement.

51 : Previous year figures re-grouped / re-classified where ever necessary

---

Mar 31, 2015

1.1 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts. All other expenses which are not attributable to segments have been disclosed as unallocable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

1.2 Accounting Standard ( As-18) " Related Party Disclosures":

a) Entities in which the Company has substantial Interest Emmessar Technologies Limited

b) Key Management Personnel and their relatives

i) MSR Ayyangar - Managing Director

ii) Dr. Anuradha Raghavan - Daughter of MSR Ayyangar

iii) Dr. Sarada Raghavan - Daughter of MSR Ayyangar

1.3 Due to/ from parties are subject to confirmation.

1.4 In the opinion of the Board all the current Assets, Loans and Advances deposits are realisable at value stated in ordinary course of business which are atleast equal to the amount at which they are stated in the books unless otherwise stated.

1.5 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its non resident shareholders during the current year as well as previous year

1.6 The company is in the proces of evaluating various business opportunities within the pharmaceutical and health care industry. These business plans when implemented will have positive impact on the financial performance and absorb all the lossess. Accordingly, the company is of the view that going concern assumption is not affected.

1.7 Previous year figures have been regrouped/ reclassified to correspond with the curent year classification disclosure

---

Mar 31, 2014

Particulars

Year Ended31.3.2014 Year Ended 31.3.2013

1.1 COMMITMENTS & CONTINGENT LIABILITIES

a) Estimated Amount of Contract remains to be executed and not provided for in the accounts NIL NIL

b) Claims against the Company not acknowledges as Debts NIL NIL

D. Other Long Term Benefits The Company''s does not have any other Long Term benefits

1.2 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts.All other expenses which are not attributable to segments have been disclosed as unallocable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

Particulars - for the year ended March 31, 2014

1.3 Accounting Standard ( As-18) " Related Party Disclosures":

a) Entities in which the Company has substantial Interest Emmessar Technologies Limited

b) Key Management Personnel and their relatives

i) MSR Ayyangar - Managing Director

ii) Dr. Anuradha Raghavan - Daughter of MSR Ayyangar

iii) Dr. Sarada Raghavan - Daughter of MSR Ayyangar Details of the transactions with above parties

Financial transactions have been carried out in the ordinary course of business and/ or in discharge of contractual obligations

1.4 Due to/ from parties are subject to confirmation.

1.5 In the opinion of the Board all the current Assets, Loans and Advances deposits are realisable at value stated in ordinary course of business which are atleast equal to the amount at which they are stated in the books unless otherwise stated.

1.6 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its non resident shareholders during the current year as well as previous year

1.7 Value of Imports on CIF Basis

1.8 The company is in the proces of evaluating various business opportunities within the pharmaceutical and health care industry. These business plans when implemented will have positive impact on the financial performance and absorb all the lossess. Accordingly, the company is of the view that going concern assumption is not affected.

1.9 Previous year figures have been regrouped/ reclassified to correspond with the curent year classification disclosure

---

Mar 31, 2013

A. Corporate Information

Emmessar Biotech & Nutrition Limited is a public limited company domiciled in India incorporated under the provisions of the Companies Act, 1956. Its shares are listed in the Bombay Stock Exchange. The Company is engaged in manufacturing and marketing Healthcare / pharmaceuticals products and chemicals. The Company caters to both domestic and international markets.

1.1 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts. All other expenses which are not attributable to segments have been disclosed as unallowable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are disclosed as unallowable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

1.2 Accounting Standard ( As-18) " Related Party Disclosures":

a) Entities in which the Company has substantial Interest Emissary Technologies Limited

b) Key Management Personnel and their relatives

i) MSR Ayyangar - Managing Director

ii) A.V.Vardharajan - Executive Director ( Worked up to January 2013)

iii) A.V. Saranagaranjan - Brother of A.V. Vardharanjan( Worked up to October 2012)

iv) Vasudevan Raghavan - Son of MSR Ayyangar (Worked up to August 2012)

1.3 The Company has incurred net loss during the year and it has also brought forward unabsorbed depreciation and business loss from previous years as per books of account as well as under the Income Tax Act, 1961. In view thereof no provision for Income Tax including Minimum Alternate Tax on Book Profits has been made in the accounts. However net Deferred Tax Asset has not been recognized, as there is uncertainty of the realization thereof in the future.

1.4 Due to/ from parties are subject to confirmation.

1.5 In the opinion of the Board all the current Assets, Loans and Advances deposits are realizable at value stated in ordinary course of business which are at least equal to the amount at which they are stated in the books unless otherwise stated.

1.6 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its nonresident shareholders during the current year as well as previous year.

---

Mar 31, 2012

A. Corporate Information

Emmessar Biotech & Nutrition Limited is a public limited company domiciled in India incorporated under the provisions of the Companies Act, 1956. Its shares are listed in the Bombay Stock Exchange. The Company is engaged in manufacturing and marketing Healthcare / pharmaceuticals products and chemicals. The Company caters to both domestic and international markets.

1.1 COMMITMENTS & CONTINGENT LIABILITIES

a) Estimated Amount of Contract remains to be executed and not provided for in the accounts (Net of Payments Made) in respect of Capital Assets NIL NIL

b) Claims against the Company not acknowledges as Debts NIL NIL

D. Other Long Term Benefits

The Company's does not have any other Long Term benefits

1.2 Accounting Standard (AS-17) "Segment Reporting":

The Company has identified business segments as its primary segment. Business segments are primarily Healthcare and Fine Chemicals Revenues and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reportable segment have been allocated on the basis of associated revenues of the segment and manpower efforts.AII other expenses which are not attributable to segments have been disclosed as unallocable expenses. Assets and liabilities that are directly attributable or allocable to segments are disclosed under each reportable segment. All other assets and liabilities are discolosed as unallocable. Fixed assets that are used interchangeably amongst segments are not allocated to primary segments.

1.3 The Company has incurred net loss during the year and it has also brought forward unabsorbed depreciation and business loss from previous years as per books of account as well as under the Income Tax Act, 1961. In view thereof no provision for Income Tax including Minimum Alternate Tax on Book Profits has been made in the accounts. However net Deferred Tax Asset has not been recognised, as there is uncertanity of the realization thereof in the future.

1.4 Due to/ from parties are subject to confirmation.

1.5 In the opinion of the Board all the current Assets, Loans and Advances deposits are realisable at value stated in ordinary course of business which are atleast equal to the amount at which they are stated in the books unless otherwise stated.

1.6 As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its non resident shareholders during the current year as well as previous year.

1.7 The Revised Schedule VI has become effective from 1st April 2011 for the preparation of financial statements. This has significantly impacted the disclosure and presentation made in the financial statements. Previous Years figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification/ disclosure.

---

Mar 31, 2010

1. a) Contingent Liabilities: NIL

b) Estimated amount of contracts remaining to be executed on capital account and not provided for (Net of Advances) : NIL

2. Registration is pending for 2 residential flats included in buildings shown in the Schedule III of Fixed Assets.

3. The Company has incurred net loss during the year and it has also brought forward unabsorbed depreciation and business losses from previous years as per books of account as well as under the Income Tax Act, 1961. In view thereof, no Provision for Income Tax including Minimum Alternate Tax on Book Profits has been made in the accounts. However, Deferred Tax Asset has not been recognised, as there is uncertainty of the realization thereof in the future.

4. Sundry Debtors include Rs.5.82 lakhs due from customers outstanding for a considerable long period. During the year the company has recovered Rs. 1.23 Lacs from these customers. In the opinion of the management the entire amount is recoverable and hence considered good.

5. Quantitative information as required by paragraph 3 of Part II of Schedule VI to the Companies Act, 1956 (As Certified by the Management):

a) LICENSED AND INSTALLED CAPACITY - NIL b) PRODUCTION

The aforesaid remuneration does not exceed Rs. 100000/ per month or Rs. 1200000/- per annum (the effective capital of the Company is Rs. 1 Crore or more but less than Rs. 5 Crores) as provided in Part II of Schedule XIII to the Companies Act, 1956 vide Circular No. GSR 36(E) issued in connection with Remuneration Payable by the Companies having no profits or inadequate profits as payment of remuneration is approved by a resolution passed by the members in the General Meeting of the Company and the Company has not made any default in repayment of any of its debts or interest payable thereon.

6. EARNING PER SHARE

The Numerator and Denominator used to calculate Basic / Diluted Earning Per Share and the Calculated Basic / Diluted Earning Per Share is as under.

7. RELATED PARTY DISCLOSURES: List of related parties.

a) Parties where control exists — None b) Other related parties with whom transactions have taken place during the year:

i) Emmessar Technologies Limited.

c) Key Management Personnel and their Relatives

i) MSR Ayyangar (Managing Director)

ii) A.V. Vardharajan (Executive Director)

iii) A.V. Sarangarajan(Brother of A.V. Vardharajan)

iv) Vasudevan Raghavan (Son of MSR Ayyangar)

Details of remuneration to Managing Director & Executive Director are disclosed at Note No. 14 herein before.

8. In the opinion of the Management, the Current Assets, Loans and Advances are expected to produce at least equal to the amount at which they are stated in the Balance Sheet in the ordinary course of business.

9. Dues to/ from parties are subject to confirmation.

10. As no dividend has been declared during the current year as well as previous year, the Company has not remitted any dividend in foreign currency to its non- resident shareholders during the current year as well as previous year.

11. In the opinion of the Management, the provisions for all known undisputed liabilities are adequate and is neither in excess nor short of the amount reasonably considered necessary.

12. There is no amount due to "Micro or Small Enterprises" and Medium Enterprises Act, 2006. Further no interest is paid / payable in terms of section 16 of the said Act. The information regarding dues to "Micro or Small Enterprises" are given to the extent such parties have been identified on the basis of information available with the Company.

13. Additional information pursuant to the provision of Part IV of Schedule VI to the Companies Act, 1956, pertaining to Balance Sheet Abstract and Companys General Business Profit is annexed hereto.

14. Schedules "I" to "XI" form integral part of the accounts and have been duly authenticated.

15. Previous year figures have been reclassified / regrouped / recasted / rearranged wherever considered necessary to conform with the classification of the current year and to make them comparable with the current years figures.